Oestrogen and progesterone receptors in the marmoset endometrium: changes during the ovulatory cycle, early pregnancy and after inhibition of vascular endothelial growth factor, GnRH or ovariectomy.
Marmosets are widely used, but detailed studies on localisation of endometrial oestrogen receptors alpha and beta (ER alpha and ER beta ), and the progesterone receptor (PR) are lacking. These receptors were localised and semi-quantitatively analysed throughout the ovulatory cycle, weeks 2, 3 and 4 of pregnancy and after treatment with GnRH antagonist, vascular endothelial growth factor (VEGF) Trap or ovariectomy. The PR in epithelial cells increased markedly between the mid- and late proliferative phases before declining in the mid-secretory phase and pregnancy. PR in stromal cells was present throughout the cycle and levels were maintained in pregnancy. ER alpha was present at the mid-proliferative phase and increased in glands at the late proliferative and early secretory phases, before declining at the late secretory phase and week 4 of pregnancy. Stromal ER alpha showed a similar trend, but decreased earlier, by the mid-secretory phase. ER beta was highly expressed in epithelial cells throughout the cycle and in pregnancy. In stroma, increases in ER beta expression were observed at the late proliferative phase with the staining index decreasing by half as the secretory phase progressed and in pregnancy. GnRH antagonist, VEGF Trap or ovariectomy caused significant reductions in PR and ER beta expression, but not in ER alpha when compared with the late proliferative phase of the normal cycle. Endothelial cells expressed ER beta , but not ER alpha or PR. It is concluded that the steroid receptor profile in the marmoset endometrium is generally similar to the human and should provide a useful model for studies on hormonal manipulation of the endometrium.
Silvestri
Audrey
A
Medical Research Council Human Reproductive Sciences Unit, The Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK.
Fraser
Hamish M
HM
D000818:Animals; D002144:Callithrix / Q000378:metabolism*; D004717:Endometrium / Q000737:chemistry* / Q000187:drug effects / Q000378:metabolism; D004958:Estradiol / Q000097:blood; D047628:Estrogen Receptor alpha / Q000032:analysis; D047629:Estrogen Receptor beta / Q000032:analysis; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D007150:Immunohistochemistry; D008597:Menstrual Cycle / Q000378:metabolism*; D009842:Oligopeptides / Q000494:pharmacology; D010052:Ovariectomy; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000378:metabolism*; D011374:Progesterone / Q000097:blood; D011960:Receptors, Estrogen / Q000032:analysis*; D017978:Receptors, Growth Factor; D011980:Receptors, Progesterone / Q000032:analysis*; D011993:Recombinant Fusion Proteins / Q000494:pharmacology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D009842:Oligopeptides; D011960:Receptors, Estrogen; D017978:Receptors, Growth Factor; D011980:Receptors, Progesterone; D011993:Recombinant Fusion Proteins; C460365:VEGF Trap R1R2 protein; D042461:Vascular Endothelial Growth Factor A; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol; C084350:antarelix